Raloxifene and estrogen reduces progression of advanced atherosclerosis — a study in ovariectomized, cholesterol-fed rabbits
- 1 January 2001
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 154 (1) , 97-102
- https://doi.org/10.1016/s0021-9150(00)00470-6
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly and Company
This publication has 18 references indexed in Scilit:
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Norethindrone Acetate Enhances the Antiatherogenic Effect of 17β-EstradiolArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits.Journal of Clinical Investigation, 1997
- Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular DiseaseNew England Journal of Medicine, 1996
- The impact of female sex hormones on secondary prevention of atherosclerosis in ovariectomized cholesterol-fed rabbitsAtherosclerosis, 1996
- Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.Journal of Clinical Investigation, 1994
- Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits.Journal of Clinical Investigation, 1991
- Steroid receptors in breast cancer: Sources of inter-laboratory variation in dextran-charcoal assaysBreast Cancer Research and Treatment, 1987
- Menopause and the Risk of Coronary Heart Disease in WomenNew England Journal of Medicine, 1987